TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01381809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2: Placebo
Description: form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Epoetin alfa
Description: type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
Study: NCT01550770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: peripheral IV of propofol at increasing dose levels
Study: NCT00791011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
Study: NCT04851314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ICU certified ventilator
Description: Examine anesthetic consumption rates
Study: NCT03547687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Treatment
Description: An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each
Study: NCT01988935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
Study: NCT01778907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype information accompanied by a drug dosing advice
Description: Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
Study: NCT03593642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacain in ESP catheter
Description: administration of ropivacaine in ESP catheter to provide regional analgesia after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuous infusion of Iso Saline in ESP catheter
Description: administration of Iso Saline in ESP catheter to be the control group
Study: NCT03547687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation Treatment
Description: If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each
Study: NCT01033591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment
Description: Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optimized treatment according to the European Society of Cardiology guidelines
Description: Optimized treatment according to the European Society of Cardiology guidelines
Study: NCT04255602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Ticagrelor 60mg plus Aspirin 100mg for experimental group
Study: NCT01688765

Intervention type: OTHER
Intervention: Observational

Intervention type: OTHER
Intervention: Observational
Study: NCT05568017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peptide receptor radionuclide therapy with Y-90-DOTATOC
Description: Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC
Study: NCT00791011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
Study: NCT03796390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123 CAR-T cells
Description: Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
Study: NCT00610857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 monoclonal antibody and HDI
Description: One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
Study: NCT00158249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citicoline
Description: 2 gm/day, 8 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched for physical appearance
Study: NCT02894957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: : Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: : Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
Study: NCT03397745

Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: All patients applied BIS on both side (Left and Right)
Study: NCT04296305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IV after

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IV after
Study: NCT00791011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
Study: NCT04296305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given IV after
Study: NCT00791011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A dipeptide boronic acid analogue with antineoplastic activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A dipeptide boronic acid analogue with antineoplastic activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A dipeptide boronic acid analogue with antineoplastic activity.
Study: NCT02454283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanoxerine HCl
Study: NCT00791011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: A dipeptide boronic acid analogue with antineoplastic activity.
Study: NCT00608894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro (tacrolimus)
Description: LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Study: NCT00957034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch
Study: NCT02454283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00957034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 300 or 450 micrograms/day transdermal testosterone patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 300 or 450 micrograms/day transdermal testosterone patch
Study: NCT04296305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given IV after

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00731666

Intervention type: DEVICE
Group type: OTHER
Intervention: Inflatable Penile Prosthesis
Description: Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
Study: NCT03876457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
Study: NCT05209204

Intervention type: DIAGNOSTIC_TEST
Intervention: ASOCT
Description: Anterior segment imaging using RTVue XR 100 Avanti OCT platform (Optovue Inc.,Fairmont, CA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Anterior segment imaging using Oculus Pentacam HR (Oculus Optikgeräte, Wetzlar, Germany).
Study: NCT05780229

Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.

Intervention type: PROCEDURE
Intervention: Arthroscopic Decompression Surgery
Description: Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.

Intervention type: PROCEDURE
Intervention: Reverse Prosthesis
Description: The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.

Intervention type: DRUG
Intervention: Pain-Relief Medication
Description: In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.

Intervention type: DEVICE
Intervention: Reverse Prosthesis Device
Description: In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
Study: NCT01142791

Intervention type: DEVICE
Group type: OTHER
Intervention: ExAblate
Description: Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
Study: NCT02387658

Intervention type: PROCEDURE
Intervention: translesional gradient measurement
Description: Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.

Intervention type: PROCEDURE
Intervention: translesional gradient measurement
Description: Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
Study: NCT01748903

Intervention type: DEVICE
Intervention: Target 360°, 2D Coils, Nano Coils
Study: NCT03089008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Study: NCT02354690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: 7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
Study: NCT03659240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry beverage
Description: During the intervention period, research participants will consume a cranberry beverage daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: During the intervention period, research participants will consume a placebo beverage daily.
Study: NCT04399304

Intervention type: PROCEDURE
Intervention: simultaneous bilateral high tibial osteotomy
Description: One-stage simultaneous bilateral high tibial osteotomy

Intervention type: PROCEDURE
Intervention: Staged bilateral high tibial osteotomy
Description: Two-stage bilateral high tibial osteotomy
Study: NCT03350802

Intervention type: DIAGNOSTIC_TEST
Intervention: procalcitonin test
Description: All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
Study: NCT02479386

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was administered in this study.
Study: NCT02463227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump.
Study: NCT02802657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treat-and-Extend regimen
Description: For the T\&E regimen,investigators recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pro Re Nata
Description: For the PRN group, investigators recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
Study: NCT04255602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90mg plus Aspirin 100mg for active comparator group
Study: NCT03130361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Ventilation
Study: NCT04160897

Intervention type: DRUG
Intervention: Entecavir
Description: entecavir naive for chronic hepatitis B patients